Literature DB >> 12387840

Magnetic resonance imaging in cancer research.

B D Ross1, T L Chenevert, A Rehemtulla.   

Abstract

Non-invasive assessment of antineoplastic response and correlation of the location, magnitude and duration of transgene expression in vivo would be particularly useful for evaluating cancer gene therapy protocols. This review presents selected examples of how magnetic resonance (MR) has been used to assess therapeutic efficacy by non-invasive quantitation of cell kill, to detect a therapeutic response prior to a change in tumour volume and to detect spatial heterogeneity of the tumour response and quantitate transgene expression. In addition, applications of the use of bioluminescence imaging (BLI) for the evaluation of treatment efficacy and in vivo transgene expression are also presented. These examples provide an overview of areas in which imaging of animal tumour models can contribute towards improving the evaluation of experimental therapeutic agents.

Entities:  

Mesh:

Year:  2002        PMID: 12387840     DOI: 10.1016/s0959-8049(02)00387-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome.

Authors:  Bradford A Moffat; Thomas L Chenevert; Charles R Meyer; Paul E McKeever; Daniel E Hall; Benjamin A Hoff; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

2.  Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging.

Authors:  Ihab R Kamel; Eleni Liapi; Diane K Reyes; Marianna Zahurak; David A Bluemke; Jean-François H Geschwind
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

3.  Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.

Authors:  Victor D Schepkin; Kuei C Lee; Kyle Kuszpit; Mukilan Muthuswami; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  NMR Biomed       Date:  2006-12       Impact factor: 4.044

Review 4.  Diffusion imaging for evaluation of tumor therapies in preclinical animal models.

Authors:  B A Moffat; D E Hall; J Stojanovska; P J McConville; J B Moody; T L Chenevert; A Rehemtulla; B D Ross
Journal:  MAGMA       Date:  2004-12-01       Impact factor: 2.310

5.  Application of 23Na MRI to monitor chemotherapeutic response in RIF-1 tumors.

Authors:  Andriy M Babsky; Shahryar K Hekmatyar; Hong Zhang; James L Solomon; Navin Bansal
Journal:  Neoplasia       Date:  2005-07       Impact factor: 5.715

6.  Enhancing Akt imaging through targeted reporter expression.

Authors:  Limin Zhang; Mahaveer S Bhojani; Brian D Ross; Alnawaz Rehemtulla
Journal:  Mol Imaging       Date:  2008 Jul-Aug       Impact factor: 4.488

7.  Novel molecular imaging platform for monitoring oncological kinases.

Authors:  Shyam Nyati; Brian D Ross; Alnawaz Rehemtulla; Mahaveer S Bhojani
Journal:  Cancer Cell Int       Date:  2010-07-08       Impact factor: 5.722

8.  Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides.

Authors:  Jinyuan Zhou; Erik Tryggestad; Zhibo Wen; Bachchu Lal; Tingting Zhou; Rachel Grossman; Silun Wang; Kun Yan; De-Xue Fu; Eric Ford; Betty Tyler; Jaishri Blakeley; John Laterra; Peter C M van Zijl
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

9.  Exogenous Molecular Probes for Targeted Imaging in Cancer: Focus on Multi-modal Imaging.

Authors:  Bishnu P Joshi; Thomas D Wang
Journal:  Cancers (Basel)       Date:  2010-06-11       Impact factor: 6.639

10.  A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma.

Authors:  Ariane Söling; Christian Theiss; Stephanie Jungmichel; Nikolai G Rainov
Journal:  Genet Vaccines Ther       Date:  2004-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.